Biocon’s arm collaborates with RSSDI

15 Nov 2021 Evaluate

Biocon’s subsidiary -- Biocon Biologics has tied up with the Research Society for the Study of Diabetes in India (RSSDI), Asia’s largest organization of researchers and healthcare professionals for diabetes, to launch a Comprehensive Care Program, BRIDGE-1, the Biocon & RSSDI Initiative for Diabetes Knowledge in Type 1 patients.

To address the issue of Type 1 diabetes in children in a holistic manner, Biocon Biologics will work together with RSSDI to identify and train around 400 physicians in different districts across the country. Biocon Biologics will enable these HCPs with a free supply of its insulins portfolio to help over 1,000 children with Type 1 diabetes, from the marginalized communities, who otherwise cannot afford this therapy.

As a part of this initiative, RSSDI teams will develop the training material, as well as, will train these physicians, to create awareness on effective diabetes management in Type 1 patients, among their peers, and community at large in their respective districts. Biocon Biologics will provide educational and other diabetes awareness materials for these training programs as well as will facilitate organizing of these events.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

364.40 -2.15 (-0.59%)
21-Jan-2026 15:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.90
Dr. Reddys Lab 1157.45
Cipla 1370.40
Zydus Lifesciences 874.10
Lupin 2144.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×